MCID: SCH015
MIFTS: 71

Schizophrenia

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Schizophrenia

MalaCards integrated aliases for Schizophrenia:

Name: Schizophrenia 54 54 38 12 24 25 71 29 13 52 41 42 14 69
Schizophrenia 12 54 13 69
Schizoaffective Disorder 71 69
Schizophrenia 6 29 69
Schizophrenia, Susceptibility to 13
Dementia Praecox 25
Schizophrenia-1 12
Schizophrenia 1 69
Sczd 71

Characteristics:

OMIM:

54
Inheritance:
autosomal dominant

Miscellaneous:
genetic heterogeneity
onset often in late adolescence
symptoms must occur for 6 months including 1 month of characteristic symptoms (e.g. delusions) to make diagnosis
multiple gene loci involved in causation of schizophrenia


HPO:

32
schizophrenia:
Inheritance heterogeneous autosomal dominant inheritance


Classifications:



Summaries for Schizophrenia

MedlinePlus : 41 schizophrenia is a serious brain illness. people who have it may hear voices that aren't there. they may think other people are trying to hurt them. sometimes they don't make sense when they talk. the disorder makes it hard for them to keep a job or take care of themselves. symptoms of schizophrenia usually start between ages 16 and 30. men often develop symptoms at a younger age than women. people usually do not get schizophrenia after age 45. there are three types of symptoms: psychotic symptoms distort a person's thinking. these include hallucinations (hearing or seeing things that are not there), delusions (beliefs that are not true), trouble organizing thoughts, and strange movements. "negative" symptoms make it difficult to show emotions and to function normally. a person may seem depressed and withdrawn. cognitive symptoms affect the thought process. these include trouble using information, making decisions, and paying attention. no one is sure what causes schizophrenia. your genes, environment, and brain chemistry may play a role. there is no cure. medicine can help control many of the symptoms. you may need to try different medicines to see which works best. you should stay on your medicine for as long as your doctor recommends. additional treatments can help you deal with your illness from day to day. these include therapy, family education, rehabilitation, and skills training. nih: national institute of mental health

MalaCards based summary : Schizophrenia, also known as schizophrenia 12, is related to personality disorder and paranoid schizophrenia, and has symptoms including short stature, delusions and hypertelorism. An important gene associated with Schizophrenia is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways is Monoamine GPCRs. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes.

Disease Ontology : 12 A psychotic disorder that is characterized by a disintegration of thought processes and of emotional responsiveness.

Genetics Home Reference : 25 Schizophrenia is a mental health disorder classified as a psychosis, which means that it affects a person's thinking, sense of self, and perceptions. The disorder typically appears during late adolescence or early adulthood.

OMIM : 54
Schizophrenia is a psychosis, a disorder of thought and sense of self. Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. There is no characteristic pathology, such as neurofibrillary tangles in Alzheimer disease (104300). Schizophrenia is a common disorder with a lifetime prevalence of approximately 1%. It is highly heritable but the genetics are complex. This may not be a single entity. Schizophrenia and bipolar disorder (see 125480) are generally considered to be separate entities, but patients who exhibit multiple symptoms of both disorders are often given the hybrid diagnosis schizoaffective disorder (Blacker and Tsuang, 1992). (181500)

UniProtKB/Swiss-Prot : 71 Schizophrenia: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.

Wikipedia : 72 Schizophrenia is a mental disorder characterized by abnormal social behavior and failure to understand... more...

Related Diseases for Schizophrenia

Diseases in the Schizophrenia family:

Schizophrenia 9 Schizophrenia 17
Schizophrenia 16 Schizophrenia 10
Schizophrenia 19 Schizophrenia 4
Schizophrenia 15 Early-Onset Schizophrenia

Diseases related to Schizophrenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 333)
id Related Disease Score Top Affiliating Genes
1 personality disorder 32.6 COMT DISC1 DRD3 HTR2A NRG1
2 paranoid schizophrenia 12.4
3 schizophrenia 4 12.2
4 schizophrenia 17 12.1
5 schizophrenia 15 12.1
6 schizophrenia 9 12.0
7 schizophrenia susceptibility 18 12.0
8 early-onset schizophrenia 12.0
9 childhood-onset schizophrenia 12.0
10 schizophrenia 10 11.7
11 schizophrenia mental retardation deafness retinitis 11.7
12 schizophrenia 16 11.7
13 schizophrenia 19 11.7
14 bone fracture 11.6 COMT DAOA DISC1 DRD3 HTR2A MTHFR
15 chronic conjunctivitis 11.6 AKT1 COMT DAOA DISC1 DRD3 HTR2A
16 schizoaffective disorder 11.5
17 sexual disorder 11.4 COMT DISC1 DRD3 HTR2A MTHFR
18 primary angle-closure glaucoma 11.4 COMT DAO HTR2A NRG1
19 partial motor epilepsy 11.4 COMT DAOA DISC1 HTR2A
20 chitty hall webb syndrome 11.4 COMT DAOA NRG1
21 teebi kaurah syndrome 11.3 COMT DRD3 HTR2A
22 albinism, oculocutaneous, type v 11.3 COMT DRD3 HTR2A MTHFR
23 schizophreniform disorder 11.3
24 pauci-immune glomerulonephritis with anca 11.3 COMT DRD3 HTR2A
25 cecal benign neoplasm 11.2 COMT DRD3 HTR2A
26 bladder flat intraepithelial lesion 11.2 DISC1 DRD3 HTR2A
27 parkinson disease, late-onset 11.2 AKT1 COMT DRD3 HTR2A
28 psychotic disorder 11.1
29 rhinoscleroma 11.1 COMT NRG1
30 aicardi-goutieres syndrome 2 11.1 COMT DRD3 HTR2A
31 neuroleptic malignant syndrome 11.0
32 systemic lupus erythematosus 11.0
33 darier disease 11.0
34 giant cell reparative granuloma 10.9 COMT NRG1
35 syngap1-related non-syndromic intellectual disability 10.7
36 landau-kleffner syndrome 10.7
37 hyperprolinemia, type i 10.7
38 chromosome 1q21.1 deletion syndrome 10.7
39 lupus - neurological sequelae 10.7
40 social emotional agnosia 10.7
41 chromosome 15q13.3 microdeletion syndrome 10.7
42 pyromania 10.7 DRD3 HTR2A
43 bipolar disorder 10.6
44 delusional disorder 10.6
45 schizotypal personality disorder 10.6
46 tardive dyskinesia 10.4
47 neuronitis 10.3
48 mood disorder 10.2
49 bipolar i disorder 10.2
50 cerebritis 10.2

Comorbidity relations with Schizophrenia via Phenotypic Disease Network (PDN): (show all 15)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Bipolar Disorder
Decubitus Ulcer Deficiency Anemia
Heart Disease Hypothyroidism
Iron Deficiency Anemia Paranoid Schizophrenia
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder
Tardive Dyskinesia

Graphical network of the top 20 diseases related to Schizophrenia:



Diseases related to Schizophrenia

Symptoms & Phenotypes for Schizophrenia

Symptoms via clinical synopsis from OMIM:

54

Neurologic- Central Nervous System:
delusions
hallucinations
schizophrenia
social and occupational deterioration
disorganized speech
more
Laboratory- Abnormalities:
abnormal eeg in 25% hospitalized patients


Clinical features from OMIM:

181500 603013

Human phenotypes related to Schizophrenia:

32 (show all 14)
id Description HPO Frequency HPO Source Accession
1 short stature 32 HP:0004322
2 delusions 32 HP:0000746
3 hypertelorism 32 HP:0000316
4 frontal bossing 32 HP:0002007
5 hallucinations 32 HP:0000738
6 renal agenesis 32 HP:0000104
7 schizophrenia 32 HP:0100753
8 ectopic kidney 32 HP:0000086
9 flat occiput 32 HP:0005469
10 eeg abnormality 32 very rare (1%) HP:0002353
11 protruding ear 32 HP:0000411
12 social and occupational deterioration 32 HP:0007086
13 partially duplicated kidney 32 HP:0008738
14 short proximal phalanx of the 4th toe 32 HP:0100396

UMLS symptoms related to Schizophrenia:


fatigue, sleep disturbances, photophobia, personality changes, restlessness, pseudobulbar behavioral symptoms

Drugs & Therapeutics for Schizophrenia

Drugs for Schizophrenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 696)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
4
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
5
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Phase 1 146939-27-7 60854
6
Donepezil Approved Phase 4,Phase 3,Phase 2 120014-06-4 3152
7
Clozapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 5786-21-0 2818
8
Etomidate Approved Phase 4 33125-97-2 36339 667484
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
11
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1 59729-33-8 2771
12
Reboxetine Approved, Investigational Phase 4,Phase 3,Phase 1 98769-81-4, 71620-89-8 123628 65856
13
Sulpiride Approved Phase 4,Phase 3,Phase 2,Phase 1 15676-16-1 5355
14
Moxonidine Approved Phase 4 75438-57-2 4810
15
Nicotine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 54-11-5 942 89594
16
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2 249296-44-4 5310966
17
Haloperidol Approved Phase 4,Phase 3,Phase 2,Phase 1 52-86-8 3559
18
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
19
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 112111-43-0
20
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 68693-11-8 4236
21
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 10118-90-8 5281021
22
Chlorpromazine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-53-3 2726
23
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
24
Asenapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-56-2, 65576-45-6 3001386
25
Methyltestosterone Approved Phase 4 58-18-4 6010
26
Testosterone Approved, Investigational Phase 4 58-22-0 6013
27
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
28
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
29
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 75614-87-8, 51-45-6 774
30
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
31
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19982-08-2 4054
32
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-56-6 439302 53477758
33
Perphenazine Approved Phase 4,Phase 3,Phase 2 58-39-9 4748
34
Fluvoxamine Approved, Investigational Phase 4,Phase 3 54739-18-3 3404 5324346
35
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
36
Famotidine Approved Phase 4,Phase 2,Phase 3 76824-35-6 3325
37
Galantamine Approved Phase 4,Phase 2,Phase 3 357-70-0 9651
38
Pimozide Approved Phase 4,Phase 3,Phase 2 2062-78-4 16362
39
Trifluoperazine Approved Phase 4,Phase 3 117-89-5 5566
40
Menthol Approved Phase 4 2216-51-5 16666
41
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 1 50-36-2 5760 446220
42
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 1 61869-08-7 43815
43
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
44
Methotrimeprazine Approved Phase 4,Phase 3,Phase 2 60-99-1 72287
45
Amantadine Approved Phase 4,Phase 3,Phase 2,Phase 1 768-94-5 2130
46
Pramipexole Approved, Investigational Phase 4,Phase 3 104632-26-0 59868 119570
47
Mianserin Approved Phase 4,Phase 3 24219-97-4 4184
48
Mirtazapine Approved Phase 4,Phase 3,Phase 1 85650-52-8, 61337-67-5 4205
49
Cycloserine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68-41-7 401 6234
50
Hydroxocobalamin Approved Phase 4,Phase 2,Phase 3 13422-51-0 11953898 5460373 44475014

Interventional clinical trials:

(show top 50) (show all 2966)

id Name Status NCT ID Phase Drugs
1 Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia Unknown status NCT02040883 Phase 4 Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole;Tandospirone
2 Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia Unknown status NCT02210962 Phase 4
3 Magnetic Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia Unknown status NCT00186771 Phase 4
4 A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia Unknown status NCT01490567 Phase 4 Donepezil;placebo
5 The New Strategy for Pharmacological Treatment in People With Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
6 Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia Unknown status NCT02049021 Phase 4
7 Diabetes Prevention Program in Schizophrenia [DPPS] Unknown status NCT00182494 Phase 4
8 Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia Unknown status NCT01300364 Phase 4 Reboxetine;citalopram (SSRI)
9 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
10 Association of Amisulpride Response in Schizophrenia With Brain Image Unknown status NCT02095938 Phase 4 amisulpride
11 Alleviating the Metabolic Side Effects of Antipsychotic Medications Unknown status NCT01567124 Phase 4 Moxonidine;Placebo;Moxonidine;Placebo
12 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
13 Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors Unknown status NCT00802919 Phase 4 Varenicline;Placebo for varenicline
14 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4 aripiprazole
15 Identification and Treatment of the Liability to Develop Schizophrenia Unknown status NCT00305474 Phase 4 Risperidone
16 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
17 Varenicline Adjunctive Treatment in Schizophrenia Unknown status NCT00492349 Phase 4 Varenicline;Placebo
18 PREvent First Episode Relapse (PREFER) Unknown status NCT00220714 Phase 4 atypical antipsychotics:oral vs. long-acting route
19 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4 Aripiprazole;Risperidone;Modafinil
20 Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) Unknown status NCT01822418 Phase 4 agomelatine
21 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
22 Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study Unknown status NCT01133080 Phase 4 Minocycline;placebo
23 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4 Quetiapine fumarate;Haloperidol
24 Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
25 Optimization of Acute Treatment in First Episode Schizophrenia Unknown status NCT00157378 Phase 4 Risperidone, Haloperidol
26 Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype Unknown status NCT01078870 Phase 4 Lexapro;Cymbalta;Placebo
27 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
28 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
29 Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning Unknown status NCT00937261 Phase 4 Risperidone;Paliperidone
30 Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
31 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
32 Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
33 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
34 Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
35 Investigator Initiated Study - Asenapine Early Psychosis Unknown status NCT01968161 Phase 4 Asenapine
36 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
37 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
38 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
39 Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial Unknown status NCT00260390 Phase 4 Testoviron
40 Estrogen and Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
41 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
42 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
43 The Effects of Nicotine on Cognition in Schizophrenia Completed NCT00383747 Phase 4 transdermal nicotine patch;Transdermal Nicotine Patch
44 A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics Completed NCT02712463 Phase 4
45 Assertive Community Treatment (ACT) in Schizophrenia Spectrum Disorders Completed NCT01081418 Phase 4
46 Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate Completed NCT02532842 Phase 4
47 Evaluation of Mirtazapine and Folic Acid for Schizophrenia: Completed NCT01263080 Phase 4 mirtazapine;folic acid placebo;mirtazapine placebo;folic acid
48 Risperidone Maintenance Treatment in Schizophrenia Completed NCT00848432 Phase 4 risperidone
49 Folate Supplementation in Schizophrenia Completed NCT00249288 Phase 4 Folate;Placebo
50 Valproate in Late Life Schizophrenia Completed NCT00194025 Phase 4 Valproate

Search NIH Clinical Center for Schizophrenia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: schizophrenia

Genetic Tests for Schizophrenia

Genetic tests related to Schizophrenia:

id Genetic test Affiliating Genes
1 Schizophrenia 29 24 TAAR6
2 Schizophrenia 6 29

Anatomical Context for Schizophrenia

MalaCards organs/tissues related to Schizophrenia:

39
Brain, Cortex, Testes, Prefrontal Cortex, Eye, Cingulate Cortex, Heart

Publications for Schizophrenia

Articles related to Schizophrenia:

(show top 50) (show all 7034)
id Title Authors Year
1
Genetic risk between the CACNA1I gene and schizophrenia in Chinese Uygur population. ( 28725167 )
2018
2
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. ( 28839341 )
2017
3
Characteristics and Service Use of Older Adults with Schizoaffective Disorder Versus Older Adults with Schizophrenia and Bipolar Disorder. ( 28478998 )
2017
4
An Association Between Functional Polymorphisms of the Interleukin 1 Gene Complex and Schizophrenia Using Transmission Disequilibrium Test. ( 28083609 )
2017
5
Structure models of G72, the product of a susceptibility gene to schizophrenia. ( 27815320 )
2017
6
Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. ( 28941119 )
2017
7
Early-onset schizophrenia: Symptoms and social class of origin. ( 28701088 )
2017
8
Abnormal parietal encephalomalacia associated with schizophrenia: A case report. ( 28272261 )
2017
9
A promoter polymorphism rs2075824 within IMPA2 gene affecting the transcription activity: possible relationship with schizophrenia. ( 27748550 )
2017
10
The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. ( 26856250 )
2017
11
Neurocognition in patients with psychotic and non-psychotic bipolar I disorder. A comparative study with individuals with schizophrenia. ( 28709024 )
2017
12
Clinical Correlates of Treatment Response among Patients with Schizophrenia in a Tertiary Nigerian Hospital. ( 28529220 )
2017
13
Pronounced inhibition-related hypofrontal dysfunction in early-onset schizophrenia as indexed by NoGo-P300 amplitude. ( 28174035 )
2017
14
Genetic risk for schizophrenia and psychosis in Alzheimer disease. ( 28461698 )
2017
15
Elucidating the role of the pLG72 R30K substitution in schizophrenia susceptibility. ( 28166363 )
2017
16
DNA Methylation Analysis of BRD1 Promoter Regions and the Schizophrenia rs138880 Risk Allele. ( 28095495 )
2017
17
WNT/I^-Catenin Pathway and Epigenetic Mechanisms Regulate the Pitt-Hopkins Syndrome and Schizophrenia Risk Gene TCF4. ( 28879201 )
2017
18
Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment. ( 28470106 )
2017
19
Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials. ( 28528597 )
2017
20
-759C>T Polymorphism of the HTR2C Gene is Associated with Second Generation Antipsychotic-Induced Weight Gain in Female Patients with Schizophrenia. ( 27414739 )
2017
21
A Psychopathological Comparison between Delusional Disorder and Schizophrenia. ( 28595494 )
2017
22
Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial. ( 28541645 )
2017
23
Self versus informant reports on the specific levels of functioning scale: Relationships to depression and cognition in schizophrenia and schizoaffective disorder. ( 28740827 )
2017
24
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. ( 28839342 )
2017
25
Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder. ( 28923068 )
2017
26
Treatment retention of risperidone long-acting injection in patients with early-onset schizophrenia in Japan. ( 28558887 )
2017
27
Judgment of moral and social transgression in schizophrenia. ( 28531645 )
2017
28
Higher required dosage of antipsychotics to relieve the symptoms of first-onset Acute and Transient Psychotic Disorder (ATPD) predicted the subsequent diagnostic transition to schizophrenia: A longitudinal study. ( 28739289 )
2017
29
Moral cognition and homicide amongst forensic patients with schizophrenia and schizoaffective disorder: A cross-sectional cohort study. ( 28716450 )
2017
30
The impact of a TV report in schizophrenia stigma reduction: A quasi-experimental study. ( 28084154 )
2017
31
Following Instructions in Patients With Schizophrenia: The Benefits of Actions at Encoding and Recall. ( 28531307 )
2017
32
Primary cilia formation is diminished in schizophrenia and bipolar disorder: A possible marker for these psychiatric diseases. ( 28927861 )
2017
33
A study of the possible association of plasminogen activator inhibitor type 1 4G/5G insertion/deletion polymorphism with susceptibility to schizophrenia and in its subtypes. ( 27796029 )
2017
34
Asperger syndrome and schizophrenia: I9eurodevelopmental continuum or separated clinical entities? ( 28686564 )
2017
35
A Case-Control Study of the Association between Polymorphisms in the Fibrinogen Alpha Chain Gene and Schizophrenia. ( 28203040 )
2017
36
Frequency-specific alteration of functional connectivity density in antipsychotic-naive adolescents with early-onset schizophrenia. ( 28793242 )
2017
37
Very Early-onset Schizophrenia with Secondary Onset Tic Disorder. ( 28852253 )
2017
38
The serotonin transporter gene 5-HTTLPR polymorphism is associated with affective psychoses but not with schizophrenia: A large-scale study in the Russian population. ( 28029428 )
2017
39
Reelin (RELN) DNA methylation in the peripheral blood of schizophrenia. ( 28086126 )
2017
40
Phenotypic continuum between autism and schizophrenia: Evidence from the Movie for the Assessment of Social Cognition (MASC). ( 28089135 )
2017
41
Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls. ( 28091349 )
2017
42
Basic Self-Disturbances beyond Schizophrenia: Discrepancies and Affinities in Panic Disorder - An Empirical Clinical Study. ( 28259879 )
2017
43
The schizophrenia risk gene MIR137 acts as a hippocampal gene network node orchestrating the expression of genes relevant to nervous system development and function. ( 26925706 )
2017
44
Reduced Structural Connectivity in Frontostriatal White Matter Tracts in the Associative Loop in Schizophrenia. ( 28945119 )
2017
45
Aberrant spontaneous neural activity and correlation with evoked-brain potentials in first-episode, treatment-naA^ve patients with deficit and non-deficit schizophrenia. ( 28092779 )
2017
46
Bipolar I disorder in remission vs. schizophrenia in remission: Is there a difference in burden? ( 27816846 )
2017
47
Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy. ( 28953788 )
2017
48
Functional network changes and cognitive control in schizophrenia. ( 28529872 )
2017
49
Elevated mRNA expression of CASPR3 in patients with schizophrenia. ( 28413940 )
2017
50
Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. ( 28086761 )
2017